Can Obama Help Vete...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$40.08 -0.33 | -0.82%
06/01/12 - 04:01 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 6.20 | 17.40 | 17.70 |
| P/E High - Last 5 Yrs | 15.90 | 19.50 | 67.70 |
| P/E Low - Last 5 Yrs | 5.60 | 8.60 | 12.50 |
| Beta | 0.61 | 0.58 | 0.98 |
| Price to Sales (TTM) | 1.56 | 2.34 | 1.42 |
| Price to Book (MRQ) | 2.37 | 2.46 | 2.41 |
| Price to Tangible Book (MRQ) | 82.62 | 19.23 | 5.08 |
| Price to Cash Flow (TTM) | 4.50 | 9.60 | 9.80 |
| Price to Free Cash Flow (TTM) | 11.60 | 89.50 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 9.70 | 4.40 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 3.50 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | 10.00 | 5.99 | -0.76 |
| Payout Ratio (TTM) | 43.00 | 69.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -11.40 | 23.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 1.00 | 12.50 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 3.60 | 4.23 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -43.50 | 61.90 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -43.50 | 61.90 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | 8.30 | 0.81 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | 14.94 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.20 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 1.40 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.37 | 0.36 | 0.82 |
| Total Debt to Equity (MRQ) | 0.46 | 0.46 | 0.96 |
| Interest Coverage (TTM) | 12.50 | 12.00 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 89.20 | 77.40 | 46.90 |
| Gross Margin - 5 Yr Avg | 88.00 | 78.40 | 47.70 |
| EBITD Margin (TTM) | 36.00 | 30.50 | 18.90 |
| EBITD - 5 Yr Avg | 34.10 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 34.10 | 21.30 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 31.60 | 23.10 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.27 | 0.17 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 23.20 | 19.00 | 7.00 |
| Return on Assets (TTM) | 17.20 | 7.40 | 3.10 |
| Return on Assets - 5 Yr Avg | 14.40 | 9.80 | 2.50 |
| Return on Investment (TTM) | 29.70 | 11.50 | 7.90 |
| Return on Investment - 5 Yr Avg | 27.30 | 15.70 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 570,769.00 | 548,710.00 | 449,376.00 |
| Net Income/Employee (TTM) | 152,413.00 | 91,547.00 | 39,003.00 |
| Receivable Turnover (TTM) | 3.20 | 4.90 | 7.60 |
| Inventory Turnover (TTM) | 1.80 | 1.90 | 8.30 |
| Asset Turnover (TTM) | 0.60 | 0.50 | 0.40 |
Portfolios with AZN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
- User2012 performers
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
Latest AZN Headlines from TheStreet
- 9 High-Yield Stocks to Consider in Lieu of Bonds 06.01.12 | 01:06 pm
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner 05.03.12 | 05:05 pm
- The Next Big Thing in Biotech: M&A
04.27.12 | 05:04 am - AstraZeneca PLC (AZN): Today's Featured Drugs Loser 04.26.12 | 05:04 pm
- Rupert Murdoch in Second Day of Testimony: Hot Trends 04.26.12 | 08:04 am
- 14 Deal-Ready Stocks for the M&A Boom 04.26.12 | 06:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends 04.23.12 | 10:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends 04.23.12 | 08:04 am
- AstraZeneca Wins Patent Protection on Seroquel: Hot Trends 03.30.12 | 10:03 am
- Stocks to Watch: Research In Motion, Dunkin' Brands (Update 1) 03.30.12 | 08:03 am
Press Releases for AZN
- Data Presented At The European Atherosclerosis Society Congress Reinforces The Differentiating Benefits Of CRESTOR[TM] In Comparison To Atorvastatin And Simvastatin - PR Newswire 05.28.12 | 01:05 am
- SYMBICORT® (budesonide/formoterol Fumarate Dihydrate) Long-Term Study Shows Similar Safety Profile When Compared To Budesonide Monotherapy In African-American Patients With Asthma - Business Wire 05.10.12 | 09:05 am
- LUNAR Examines Cholesterol-Lowering Effects Of CRESTOR® (rosuvastatin Calcium) Compared With Atorvastatin In Patients With Acute Coronary Syndrome - Business Wire 05.01.12 | 09:05 am
- AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease - Business Wire 04.25.12 | 12:04 pm
- AstraZeneca Launches DUTOPROL™ (metoprolol Succinate Extended Release/hydrochlorothiazide) Tablets For High Blood Pressure In U.S. - Business Wire 04.12.12 | 09:04 am
- US District Court Finds SEROQUEL XR Formulation Patent Valid And Infringed - Business Wire 03.29.12 | 05:03 pm
- Crestor Delivers Latest LDL-C Targets In High-Risk Patients At Lower Doses Than Other Statins - PR Newswire 03.26.12 | 01:03 pm
- US Court Denies Preliminary Injunction Application Against The FDA And Dismisses AstraZeneca’s Lawsuit Without Prejudice - Business Wire 03.26.12 | 02:03 am
- New Data Suggests Results Of PLATO Genetic Sub-Study Outcomes For BRILINTA® (Ticagrelor) Not Driven By Poor Metabolizers Of Clopidogrel - Business Wire 03.25.12 | 11:03 am
- New Data Suggests BRILINTA® (ticagrelor) Reduced First And Recurrent Cardiovascular And Ischemic Events - Business Wire 03.25.12 | 11:03 am
Partner Headlines for AZN
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 6 FTSE100 6%+ Dividend Yielders - Seeking Alpha 05.20.12 | 08:05 am
- Merger Arbitrage Mondays - May 14, 2012 - Seeking Alpha 05.14.12 | 09:05 am
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Spectrum: Increased Fusilev Production May Boost Stock - Seeking Alpha 04.30.12 | 09:04 am
- Benzinga's M&A Chatter for Friday April 27, 2012 - Benzinga 04.28.12 | 08:04 pm
- Earnings Recap for April 26, 2012 - Benzinga 04.26.12 | 09:04 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
